Research programme: matrix metalloprotease inhibitors - Roche

Drug Profile

Research programme: matrix metalloprotease inhibitors - Roche

Alternative Names: RO 113830

Latest Information Update: 19 Sep 2006

Price : $50

At a glance

  • Originator Roche
  • Class Anti-inflammatories
  • Mechanism of Action Metalloprotease inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Osteoarthritis

Most Recent Events

  • 19 Sep 2006 Discontinued - Phase-II for Osteoarthritis in USA (PO)
  • 27 Nov 2002 A clinical study has been added to the adverse events section
  • 15 Nov 2001 A study in patients with osteoarthritis has been added to the pharmacokinetics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top